Scpharmaceuticals (NASDAQ:SCPH) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a report issued on Wednesday, Zacks.com reports. The brokerage presently has a $5.25 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 12.90% from the company’s current price.
According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “
Several other equities research analysts have also issued reports on the company. ValuEngine raised Scpharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. HC Wainwright began coverage on Scpharmaceuticals in a research report on Tuesday, October 15th. They set a “buy” rating and a $13.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Scpharmaceuticals presently has an average rating of “Buy” and an average price target of $7.75.
Scpharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. As a group, equities research analysts expect that Scpharmaceuticals will post -1.66 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Morgan Stanley increased its position in Scpharmaceuticals by 32.0% in the second quarter. Morgan Stanley now owns 13,633 shares of the company’s stock worth $43,000 after buying an additional 3,306 shares during the period. Jacobs Levy Equity Management Inc. increased its position in Scpharmaceuticals by 55.8% in the second quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock worth $118,000 after buying an additional 13,225 shares during the period. Matisse Capital acquired a new stake in Scpharmaceuticals in the third quarter worth $86,000. Paloma Partners Management Co acquired a new stake in Scpharmaceuticals in the second quarter worth $96,000. Finally, Alambic Investment Management L.P. acquired a new stake in Scpharmaceuticals in the second quarter worth $191,000. 39.92% of the stock is currently owned by hedge funds and other institutional investors.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Recommended Story: Profit margin is different from the revenue
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.